Refractory Headaches
Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-1757925
Semin Neurol 2022; 42(04): 512-522DOI: 10.1055/s-0042-1757925 1 Headache Specialist at Hartford HealthCare, Hartford, Connecticut 3 Department of Neurology, Brigham and Women's Faulkner Hospital J Graham Headache Center, Boston, Massachusetts 2 Department of Neurology at the University of Connecticut, Milford, Connecticut › Author Affiliations Medication overuse headache (MOH), new daily persistent headache (NDPH), and persistent refractory headache attributed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection represent a significant burden in terms of disability and quality of life, and a challenge in terms of definition, pathophysiology, and treatment.
Relevance: Medication overuse headache (MOH), new daily persistent headache (NDPH), and persistent refractory headache attributed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection represent a significant burden in terms of disability and quality of life, and a challenge in terms of definition, pathophysiology, and treatment. Regarding MOH, prevention without withdrawal is not inferior to prevention with withdrawal. Preventive medications like topiramate, onabotulinumtoxinA, and calcitonin gene-related peptide (CGRP) monoclonal antibodies improve chronic migraine with MOH regardless of withdrawal.